

New Information for 2023-2024

EQA / PT Programmes for
Molecular Haemato-Oncology

New Information for 2023-2024

EQA / PT Programmes for Molecular Haemato-Oncology

New Programme - We will be launching a new programme, **Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods (Pilot - Not Accredited)** to assess laboratories' ability to accurately detect and quantify MRD using next generation sequencing of the Immunoglobulin genes.

Changes to Measurable Residual Disease for AML by Molecular Methods Programme - Following several publications highlighting the importance of the detection of *FLT3* ITD MRD in acute myeloid leukaemia (1), we will be including *FLT3* MRD samples in the **MRD for AML by Molecular Methods (Pilot - Not Accredited) programme**.

1. Grob, T. *et al.* P406: Enhanced significance of *FLT3*-ITD residual disease detection on treatment outcome in acute myeloid leukaemia. *HemaSphere*: June 2022 - Volume 6 - 306-307

Myeloproliferative Neoplasms Diagnostic Testing - The number of trial issues will be increasing from one to two per annum. Each round will continue to feature a single sample.

Additional programme updates:

- We are pleased to announce that the **BCR::ABL1 Minor Quantification** programme has now been accredited to ISO 17043:2010 and in 2023-2024 will increase to three distributions of two samples per annum with performance monitoring being applied.
- As in 2022-2023, we will continue to include samples carrying alternative myeloid rearrangements, alongside the core rearrangements standardly included within the repertoire of the **BCR::ABL1 and AML Translocation Identification** programme. We aim to issue two additional educational samples across the 2023-2024 registration period. Each will feature either a pathogenic rearrangement associated with AML or an alternative *BCR::ABL1* translocation variant. Testing of the educational samples will be optional.

SEE WEBSITE FOR FULL INFORMATION ON ALL OF THE ABOVE CHANGES

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI

Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield S10 2QD
United Kingdom

Tel: +44 (0)114 2673600
Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk
www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor (and is outside of the UK) you should contact them directly for details of how to register.

If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.